Re: Successful Add-on Therapy With Eplerenone

[Guest guest]

Thanks for the update. Will add this to my next revision of the Evolution

article. Need to wait for formal publication of the results however. I

think Pfizer is missing a big oppotunity by not lowering the price of this drug

so

millions can use it.

May your pressure be low!

Clarence E. Grim, BS, MS, MD

Senior Consultant to Shared Care Research and Consulting, Inc.

(sharedcareinc.com)

Clinical Professor of Internal Medicine and Epidemiology Med. Col. WI

Clinical Professor of Nursing, Univ. of WI, Milwaukee

Specializing in Difficult to Control High Blood Pressure

and the Physiology and History of Survival During

Hard Times and Heart Disease today.

**************

Start the year off right. Easy ways to stay in shape.

http://body.aol.com/fitness/winter-exercise?NCID=aolcmp00300000002489

[Guest guest]

In a message dated 1/5/08 5:50:44 AM, riothamus2@... writes:

>

> Fascinating. DR. Grim?

>

Yes sounds like they read my evolition article. Good update for next update

of the theory.

>

> Dave

>

> airlinerg wrote:

> >

> > Successful Add-on Therapy With Eplerenone

> >

> > Also at ESC Congress 2002, further evidence was presented of the

> > efficacy of the new selective aldosterone blocker, eplerenone, as

> > add-on therapy to existing antihypertensive medication in patients

> > with uncontrolled blood pressure.[3] Researchers from Belgium,

> > Germany, Slovakia, and the United States reported a multicenter, 8-

> > week study in 272 patients whose hypertension had not been

> > controlled by calcium channel blockers (CCBs) or beta-blockers.

> > These patients were randomized to receive either eplerenone 50 mg

> > once daily (uptitrated to 100 mg if necessary) or placebo in

> > addition to their current antihypertensive therapy. The addition of

> > eplerenone significantly reduced systolic blood pressure (SBP)

> > compared with placebo (mean: -17.2 vs -10.5 mm Hg, P < .001) in the

> > CCB group and yielded significant changes in both SBP and diastolic

> > blood pressure (DBP) (mean: -19.1/-12/3 vs -11.0/-8.8 mm Hg, P

> > < .001/0.008) in the beta-blocker group. In addition, patients who

> > took eplerenone had a significantly higher response rate than those

> > on placebo (75.4% vs 68.2%, P = .002).

> >

> > These data followed similar results from another recently published,

> > 8-week, international multicenter study in which 341 patients whose

> > blood pressure was not controlled on an angiotensin- blood pre

> > enzyme (ACE) inhibitor or an ARB were similarly randomized to

> > eplerenone or placebo.[4] In this trial, the addition of eplerenone

> > resulted in significant reductions in SBP in both the ACE and ARB

> > groups compared with placebo (mean: -13.4 vs -7.5 mm Hg and -16.0

> > vs -9.2 mm Hg, respectively) and a significant reduction in DBP in

> > the ARB group only (-12.7 vs -9.3 mm Hg). Adverse events in both

> > studies were generally nonsevere, and no

> > antiandrogenic/ antiandrogenic/<wbr>progestatio

> >

> > The researchers acknowledge that the issue of whether the additional

> > reduction in blood pressure produced by selective aldosterone

> > blockade confers further cardiovascular benefits remains unresolved

> > and cannot be assessed in as short a period as 8 weeks. However,

> > they point out that recent studies of eplerenone plus enalapril have

> > suggested an additive effect on surrogate markers of end-organ

> > damage, such as echocardiographic parameters of LVH and

> > microalbuminuria in diabetic patients.[5, m

> >

> > >From the article:

> >

> > Hypertension Update

> > Revisiting the Debate: Are All Antihypertensive Agents Created Equal?

> > <http://www.medscapehttp://www.medschttp://>

> >

>

>

[Guest guest]

Fascinating. DR. Grim?

Dave

airlinerg wrote:

>

> Successful Add-on Therapy With Eplerenone

>

> Also at ESC Congress 2002, further evidence was presented of the

> efficacy of the new selective aldosterone blocker, eplerenone, as

> add-on therapy to existing antihypertensive medication in patients

> with uncontrolled blood pressure.[3] Researchers from Belgium,

> Germany, Slovakia, and the United States reported a multicenter, 8-

> week study in 272 patients whose hypertension had not been

> controlled by calcium channel blockers (CCBs) or beta-blockers.

> These patients were randomized to receive either eplerenone 50 mg

> once daily (uptitrated to 100 mg if necessary) or placebo in

> addition to their current antihypertensive therapy. The addition of

> eplerenone significantly reduced systolic blood pressure (SBP)

> compared with placebo (mean: -17.2 vs -10.5 mm Hg, P < .001) in the

> CCB group and yielded significant changes in both SBP and diastolic

> blood pressure (DBP) (mean: -19.1/-12/3 vs -11.0/-8.8 mm Hg, P

> < .001/0.008) in the beta-blocker group. In addition, patients who

> took eplerenone had a significantly higher response rate than those

> on placebo (75.4% vs 68.2%, P = .002).

>

> These data followed similar results from another recently published,

> 8-week, international multicenter study in which 341 patients whose

> blood pressure was not controlled on an angiotensin-converting

> enzyme (ACE) inhibitor or an ARB were similarly randomized to

> eplerenone or placebo.[4] In this trial, the addition of eplerenone

> resulted in significant reductions in SBP in both the ACE and ARB

> groups compared with placebo (mean: -13.4 vs -7.5 mm Hg and -16.0

> vs -9.2 mm Hg, respectively) and a significant reduction in DBP in

> the ARB group only (-12.7 vs -9.3 mm Hg). Adverse events in both

> studies were generally nonsevere, and no

> antiandrogenic/progestational effects occurred.

>

> The researchers acknowledge that the issue of whether the additional

> reduction in blood pressure produced by selective aldosterone

> blockade confers further cardiovascular benefits remains unresolved

> and cannot be assessed in as short a period as 8 weeks. However,

> they point out that recent studies of eplerenone plus enalapril have

> suggested an additive effect on surrogate markers of end-organ

> damage, such as echocardiographic parameters of LVH and

> microalbuminuria in diabetic patients.[5,6]

>

> >From the article:

>

> Hypertension Update

> Revisiting the Debate: Are All Antihypertensive Agents Created Equal?

> <http://www.medscape.com/viewarticle/441616>

>